# Tocilizumab for Patients With Cancer and COVID-19 Disease

> **NCT04370834** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Pneumonia
- Pneumonitis
- Severe Acute Respiratory Distress Syndrome
- Symptomatic COVID-19 Infection Laboratory-Confirmed

## Interventions

- **BIOLOGICAL:** Tocilizumab

## Key facts

- **NCT ID:** NCT04370834
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-28
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-01-14
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Other - Randomized data no longer support continuation
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04370834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04370834, "Tocilizumab for Patients With Cancer and COVID-19 Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04370834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*